Skip to content

Study · Non-randomized trial · 2001

2 results

Soluble ICAM-1 levels in the serum of endometriotic patients appear to be independent of medical treatment.

Matalliotakis IM, Vassiliadis S, Goumenou AG, Athanassakis I, Koumantakis GE, Neonaki MA, Koumantakis EE

Journal of reproductive immunology1 Jul 2001Cited by 20 (Europe PMC)

PMID11438377 (opens in a new tab)DOI10.1016/s0165-0378(01)00064-x (opens in a new tab)PepBankPUB-11438377
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialMechanism

    In women with endometriosis, six months of leuprorelin depot treatment increased serum soluble ICAM-1 levels.

    In plain wordsIn women with endometriosis, leuprorelin increased blood soluble ICAM-1 levels compared with pretreatment levels.

    Peptide
    Leuprolide
    Outcome
    IncreaseSerum soluble ICAM-1 during treatment
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    3.75 mg every 28 days · 6 monthsAs given in this study (human).

    Measurements

    P value
    < 0.001
    sICAM-1 increase

    Source sentences

    Summary
    (2) the 6 month treatment with danazol or leuprorelin acetate depot increased sICAM-1 levels (P<0.001)
    1 context sentence
    Summary · context
    Thirty-eight women, 18-45 years of age, with regular menses and documented pelvic endometriosis were recruited from a University Hospital setting. Twenty-two women with endometriosis were randomly divided into two groups. Danazol (600 mg) were given every day for 6 months, and 3.75 mg of leuprorelin…
  2. 02HumanNon-randomized trialMechanism

    In women with endometriosis, serum soluble ICAM-1 levels were unchanged three months after leuprorelin treatment ended.

    In plain wordsIn women with endometriosis, soluble ICAM-1 levels remained unchanged three months after leuprorelin treatment ended.

    Peptide
    Leuprolide
    Outcome
    No significant changeSerum soluble ICAM-1 after treatment termination
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    3.75 mg every 28 days · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    (3) 3 months after termination of both treatments, sICAM-1 levels were unchanged.
    1 context sentence
    Summary · context
    Thirty-eight women, 18-45 years of age, with regular menses and documented pelvic endometriosis were recruited from a University Hospital setting. Twenty-two women with endometriosis were randomly divided into two groups. Danazol (600 mg) were given every day for 6 months, and 3.75 mg of leuprorelin…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.